Home › Pharmacology › Sodium Heparin

Sodium Heparin

Q: What laboratory parameters must be monitored during unfractionated heparin therapy?

aPTT (activated partial thromboplastin time) — mandatory repeated measurements to monitor treatment efficacy.Platelet count in the blood — measured before therapy and on days 1, 3, 5, 7, 9, and 11–14 of treatment.Additional tests — antithrombin level, thrombin time, and thrombin-heparin clotting time (indicated when aPTT changes do not correlate with the administered dose).

Q: In which specific conditions is intravenous sodium heparin indicated?

Deep vein thrombosis and venous thromboembolic events — continuous IV infusion of unfractionated heparin is a method of choice in appropriate clinical scenarios.Pulmonary embolism — IV infusion is indicated for DVT with high-risk PE and early mortality risk when reperfusion is indicated.Acute coronary syndrome (unstable angina, myocardial infarction) — these are established indications for heparin, though specific intravenous routes depend on clinical protocols.

Q: What are the absolute contraindications to systemic sodium heparin use?

Active bleeding (haemorrhagia) — an absolute contraindication for all heparins.Thrombocytopenia (thrombocytopenia) — platelet count below $25 \times 10^9$/L.Heparin-induced thrombocytopenia (thrombocytopenia inducta a heparino) — history of HIT.Renal failure (insufficientia renalis) — severe impairment.

Heparini natrium

For medical students2 min readUpdated 2026-10-10

Sodium heparin is an antithrombin-dependent anticoagulant belonging to the class of agents affecting the blood coagulation system. It is an endogenous sulfated glycosaminoglycan used for rapid inhibition of blood clotting.

Pharmacological groupAgents affecting the blood system, anticoagulant

Chemical natureSulfated glycosaminoglycan (mucopolysaccharide)

FormulationsVials 5 mL (5,000, 10,000, 20,000 IU/mL); ointment 25.0

Routes of administrationIntravenous, intramuscular, subcutaneous, topical

Mechanism of Action

Standard unfractionated heparin (UFH) is a heterogeneous mixture of fractions with molecular weights ranging from 5,000 to 30,000 Da (average molecular mass of approximately 15,000 Da). It is synthesized by mast cells in the body and stored in the liver, lungs, and intestinal mucosa (industrially extracted from porcine intestinal mucosa or bovine lung).

Its pharmacological effect is based on the activation of antithrombin III. Standard heparin molecules have a sufficient chain length (about 40 monosaccharide units) to simultaneously bind antithrombin III and thrombin. Consequently, unfractionated heparin inhibits thrombin (factor IIa) and factor Xa equally (activity ratio of 1:1). Due to its large molecular structure and high hydrophilicity, heparin has a very small volume of distribution ($V_d \approx 3$–3.6 L), remaining predominantly within the vascular bed.

Pharmacological Effects

In addition to its anticoagulant action, heparin exhibits distinct pleiotropic (non-anticoagulant) effects:

Anti-atherosclerotic action: Stimulates the release of lipoprotein lipase, which hydrolyzes triglycerides within VLDL, and inhibits the proliferation of vascular smooth muscle cells.
Anti-inflammatory action: Inhibits hyaluronidase, thereby reducing vascular wall permeability.
Fibrinolytic activity: Promotes the release of tissue plasminogen activator ($tPA$) from the endothelium.
Effect on primary hemostasis: May reduce platelet aggregation, which, combined with fibrinolysis, increases the risk of bleeding.

Indications and Dosing

The drug is used in conditions requiring rapid anticoagulation for the prevention and treatment of thrombosis.

Parenteral administration: IV, IM, and SC. Intravenous administration is typically 5,000–10,000 IU every 4–6 hours.
Topical application: Heparin ointment (1 g contains 100 IU). A 3–4 cm strip of ointment is applied as a thin layer to the skin 1–3 times daily.

Side Effects and Complications

Unfractionated heparin therapy is associated with several serious adverse reactions:

Heparin-Induced Thrombocytopenia (HIT): Divided into early benign (days 2–4) and late immune-mediated (days 5–12) thrombocytopenia. The late form is dangerous due to the formation of the heparin–platelet factor 4 complex and the synthesis of IgG antibodies, leading to paradoxical thrombin generation, thrombosis (myocardial infarction, stroke, limb gangrene), and skin necrosis.
Effects on bone tissue: Increases parathyroid hormone activity, stimulating bone resorption and creating a risk of osteoporosis with prolonged use.
Electrolyte disturbances: Inhibits aldosterone synthesis in the adrenal glands, creating a risk of hyperkalemia.
Other effects: Reversible alopecia, allergic reactions (skin rash, arthralgia), and elevated liver transaminases.

Clinical Considerations and Antagonism

In the event of hemorrhagic complications or overdose, a mechanism of chemical antagonism is employed. The specific antidote for heparin is protamine sulfate, which chemically binds to the anionic centers of heparin, neutralizing its anticoagulant effect.

Important clinical limitation: In confirmed heparin-induced thrombocytopenia (HIT), the use of low-molecular-weight heparins (LMWHs) is strictly contraindicated due to the risk of cross-reactive immune responses.

Mnemonic

HEPARin: HEnerates PAradoxical Risk (HIT and thrombosis during anticoagulant therapy).

Frequently asked questions

What laboratory parameters must be monitored during unfractionated heparin therapy?

aPTT (activated partial thromboplastin time) — mandatory repeated measurements to monitor treatment efficacy.
Platelet count in the blood — measured before therapy and on days 1, 3, 5, 7, 9, and 11–14 of treatment.
Additional tests — antithrombin level, thrombin time, and thrombin-heparin clotting time (indicated when aPTT changes do not correlate with the administered dose).

In which specific conditions is intravenous sodium heparin indicated?

Deep vein thrombosis and venous thromboembolic events — continuous IV infusion of unfractionated heparin is a method of choice in appropriate clinical scenarios.
Pulmonary embolism — IV infusion is indicated for DVT with high-risk PE and early mortality risk when reperfusion is indicated.
Acute coronary syndrome (unstable angina, myocardial infarction) — these are established indications for heparin, though specific intravenous routes depend on clinical protocols.

What are the absolute contraindications to systemic sodium heparin use?

Active bleeding (haemorrhagia) — an absolute contraindication for all heparins.
Thrombocytopenia (thrombocytopenia) — platelet count below $25 \times 10^9$/L.
Heparin-induced thrombocytopenia (thrombocytopenia inducta a heparino) — history of HIT.
Renal failure (insufficientia renalis) — severe impairment.

What is the main cellular source of endogenous heparin?

Endogenous heparin is synthesized by mast cells and stored in their secretory granules (primarily in the liver, lungs, and intestinal mucosa).

What is the pathogenesis of late immune-mediated heparin-induced thrombocytopenia (HIT)?

It develops on days 5–12 of therapy and is associated with the release of platelet factor 4 (PF4), complex formation with heparin, synthesis of IgG antibodies, and endothelial damage, leading to paradoxical thrombosis.

Which drug is the specific chemical antidote for sodium heparin?

Protamine sulfate. It engages in chemical antagonism by binding to the anionic centers of heparin and completely neutralizing its anticoagulant effect.

What is the ratio of anti-Xa to anti-IIa activity characteristic of standard heparin?

Standard heparin inhibits thrombin (factor IIa) and factor Xa equally, meaning their activity ratio is 1:1.

Go deeper

Low-Molecular-Weight Heparins (LMWHs): production via depolymerization, selectivity, and pharmacokinetic differences
Heparinoids as a distinct group (sulodexide, danaparoid sodium)
Comparative bioavailability analysis of unfractionated heparin and LMWHs upon subcutaneous administration
Laboratory monitoring criteria (aPTT) during standard heparin therapy
Pleiotropic effects of heparin: impact on lipid metabolism and vascular wall proliferation